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A xenotropic murine leukemia virus–related virus (XMRV)
has recently been reported in association with prostate cancer
and chronic fatigue syndrome, with a prevalence of up to
3.7% in the healthy population. We looked for XMRV in 230
patients with human immunodeficiency virus type 1 or hep-
atitis C infection. XMRV was undetectable in plasma or pe-
ripheral blood mononuclear cells by polymerase chain re-
action targeting XMRV gag or env. T cell responses to XMRV
Gag were undetectable in peripheral blood mononuclear cells
by ex vivo gamma interferon enzyme-linked immunospot
assay. In our cohorts, XMRV was not enriched in patients
with blood-borne or sexually transmitted infections from the
United Kingdom and Western Europe.
Xenotropic murine leukemia virus-related virus (XMRV) is a
gammaretrovirus which has been linked with prostate cancer
[1, 2] and chronic fatigue syndrome [3]. XMRV was first de-
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scribed in prostate tumor samples from the United States [1,
2], but the virus could not be detected in a subsequent survey
of 589 German patients with prostate cancer [4]. Two other
surveys in Europe [5] and in Ireland [6] also failed to find the
virus. The reason for the discrepancy is not clear. More recently,
XMRV was detected in 67% of patients with chronic fatigue
syndrome in the United States [3], however 4 additional studies
examining cases of chronic fatigue syndrome diagnosed in Eu-
rope and the United States identified no cases of XMRV in-
fection [7–10].
In one of these, Groom et al [8] also looked for neutralizing
antibodies to XMRV and found that ∼1% of serum samples
tested had evidence of neutralization that could not be dis-
missed as nonspecific binding. These and other data suggest
the prevalence of XMRV in the healthy population may lie
between 1% and 3.7% [3, 8]. This has potential implications
for blood transfusion recipients and is currently under inves-
tigation by the Centers for Disease Control and Prevention and
the Department of Health and Human Services in the United
States.
The route of transmission of XMRV has not been elucidated.
We identified individuals who were at high risk for either sex-
ually transmitted or blood-borne infections, according to
whether they were infected with human immunodeficiency vi-
rus type 1 (HIV-1) or hepatitis C. We tested plasma and pe-
ripheral blood mononuclear cells (PBMCs) to reveal whether
these patients were at increased risk of XMRV infection.
Methods. Two cohorts of HIV-1–infected individuals were
tested for XMRV, 1 for patients with acute and 1 for those with
chronic HIV-1 infection (Table 1). The cohort of patients with
chronic infection included Swiss participants from the Swiss-
Spanish Intermittent Therapy Trial, described elsewhere [11].
All patients were not receiving therapy at the time of sampling
and had received a median duration of 26 months (range, 8.5–
44.5 months) of highly active antiretroviral therapy at study
entry. The median time not receiving therapy for the cohort
was 14 months (range, 3–19 months). The second HIV-1–
infected group of patients were recruited from a study of acute
HIV-1 infection at St. Mary’s Hospital, London [12]. Plasma
samples were obtained from these individuals prior to receipt
of antiretrovirals. For both cohorts, plasma samples and PBMCs
were stored in 80C freezers and liquid nitrogen, respectively,
for up to 6 years.
The cohort of hepatitis C–positive individuals was recruited
from the John Radcliffe hospital, Oxford, United Kingdom
(Table 1). All patients had chronic infection and were treatment
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Table 1. Patient Cohort Characteristics
Characteristic
Patient cohort
Chronic HIV-1 infectiona
(n p 133)
Acute HIV-1 infectiona
(n p 101)
HCV infection
(n p 67)
Sex, ratio male:female 92:41 92:9 53:14
Age, median years (range) 40 (22–68) 31 (20–67) 50 (29–81)
Available for testing 84 79 67
CD4 count pretherapy, median cells/mL (range) 359 (1–1035) 510 (90–1480) …
Viral RNA pretherapy, median log10 copies/mL (range) 4.41 (2.23–6.11) 4.95 (1.90–5.95) …
Antiretroviral therapy
Received dual therapy 10 0 …
Received triple therapy 123 0 -
Route of acquisition or risk factor
MSM 50 (38) 89 (88) …
Heterosexual 60 (45) 12(12) …
IVDU 23 (17) 0 (0) 51 (76)
Blood transfusion … … 10 (15)
Otherb … … 9 (13)
NOTE. Data are no. or no. (%) of patients, unless otherwise indicated. HCV, hepatitis C virus; HIV-1, human immunodeficiency virus type
1; IVDU, intravenous drug user; MSM, men who have sex with men.
a Patients with chronic HIV-1 infection were from the Swiss-Spanish Intermittent Therapy Trial cohort, and those with acute HIV-1 infection
were from St Mary’s Hospital acute HIV-1 cohort.
b Other includes tattoos (6), acupuncture (1), blood product recipient (1), and vaccination (1). Three patients in the HCV cohort had 11 risk
factor.
naive. Enzyme-linked immunospot (ELISPOT) assays were per-
formed using cryopreserved PBMCs ( ) or whole bloodnp 12
( ), when they were performed fresh. For the 67 poly-np 2
merase chain reactions (PCR), DNA was extracted from cryo-
preserved PBMCs ( ), fresh PBMCs ( ), or wholenp 11 np 20
blood ( ). All patients gave informed consent for en-np 36
rollment in their respective studies, according to the relevant
ethics committees.
DNA was extracted from to PBMCs or whole6 63 10 5 10
blood (Puregene DNA extraction kit), and 200–800 ng were
used in each PCR reaction. Patient plasma samples (1 mL)
underwent ultracentrifugation at 21,185 g at 4C for 1 h and
was resuspended in 140 mL of plasma. Viral RNA was extracted
(Qiagen viral RNA extraction kit) and converted to comple-
mentary DNA (cDNA) with use of random decamers and Su-
perscript II reverse transcriptase (Invitrogen). When amplifying
genomic DNA, a house-keeping gene (hGAPDH) was incor-
porated. For each run, 2 negative water controls and a separate
positive control XMRV DNA were included (XMRV plasmid
VP-62, a generous gift from Dr Robert Silverman), of which
PCR reactions were able to detect at least 5 plasmid copies,
determined by absorbance measurements at 260 nm.
To amplify XMRV, we targeted the gag and env genes with
use of nested PCR reactions described elsewhere [1, 3]. For the
gag PCR, we used 2 mL of DNA or cDNA template, 5mL of
10 reaction buffer (Invitrogen), 1 mL of 50 mmol/L MgCl2,
1 mL of 10 mmol/L dNTPs, 0.75 mL of 20 mmol/L primer GAG-
O-F (5′-CGCGTCTGATTTGTTTTGTT-3′), 0.75 mL of 20
mmol/L primer GAG-O-R (5′-CCGCCTCTTCTTCATTGTTC-
3′), 0.2 mL of Platinum Taq (Invitrogen), and water to make
up a 50-mL final volume. Conditions were incubation at 95C
for 4 min, followed by 35 cycles of 94C for 30 s, 52C for 30
s, and 72C for 45 s, and a final incubation of 72C for 7 min.
From this first-round reaction, 3 mL were used in a nested
second round with use of 5 mL of 10 reaction buffer (Invi-
trogen), 1.5 mL of 50 mmol/L MgCl2, 1 mL of 10 mmol/L dNTPs,
0.75 mL of 20mmol/L primer GAG-I-F (5′-TCTCGAGATCATG-
GGACAGA-3′), 0.75 ml of 20 mmol/L primer GAG-I-R (5′-
AGAGGGTAAGGGCAGGGTAA-3′), 0.2 mL of Platinum Taq
(Invitrogen), and water to make up a 50-mL reaction volume.
Conditions for the second round were an incubation at 95C
for 4 min, followed by 35 cycles of 94C for 30 s, 54C for 30
s, and 72C for 45 s, and a final incubation of 72C for 7 min.
The resulting fragment was 413 bp in size. For the GAPDH
PCR reaction, the primers used were HGAPDH-F (5′-GAAGG-
TGAAGGTCGGAGTC-3′) and HGAPDH-R (5′-GAAGATGG-
TGATGGGATTTC-3′), with the same reaction conditions as
the first round Gag PCR.
The env PCR reaction included 2 mL of DNA or cDNA
template, 5 mL of 10 reaction buffer (Invitrogen), 1 mL of 50
mmol/L MgCl2, 1 mL 10 mmol/L dNTPs, 0.75 mL of 20 mmol/
L primer 5922F (5′-GCTAATGCTACCTCCCTCCTGG-3′),
0.75 mL of 20 mmol/L primer 6273R (5′-GGAGCCCACTGAG-
GAATCAAAACAGG-3′), 0.2mL Platinum Taq (Invitrogen), and
water to make up a 50-mL reaction volume. Reaction conditions
were an incubation at 95C for 4 min, followed by 45 cycles
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Table 2. Assay Results for the Identification of Xenotropic Murine Leukemia Virus–Related
Virus (XMRV)
Cohort,a assay Disease stage Sample
No. of
samples tested
No. of
positive results
HIV-1 infection
Gag PCR Chronic DNA 84 0
Env PCR Chronic DNA 84 0
Gag RT-PCR Acute RNA 79 0
Env RT-PCR Acute RNA 77 0
ELISPOT Acute PBMCs 49 0
HCV
Gag PCR Chronic DNA 67 0
Env PCR Chronic DNA 67 0
ELISPOT Chronic PBMCs 14 0
NOTE. HIV-1, human immunodeficiency virus type 1; PBMC, peripheral blood mononuclear cell; PCR, poly-
merase chain reaction; RT-PCR, reverse transcription PCR.
a Patients with chronic HIV-1 infection were from the Swiss-Spanish Intermittent Therapy Trial cohort, patients
with acute HIV-1 infection were from St Mary’s Hospital acute HIV-1 cohort, and patients with chronic HCV were
from the John Radcliffe Hospital viral hepatitis clinic.
of 94C for 30 s, 57C for 30 s, and 72C for 45 s, and then a
final incubation of 72C for 7 min. From this first-round re-
action, 3 mL were used in a nested second round reaction with
the following conditions: 5 mL of 10 reaction buffer (Invi-
trogen), 1.5 mL of 50 mmol/L MgCl2, 1mL of 10 mmol/L dNTPs,
0.75 mL of 20 mmol/L primer 5942F (5′-GGGGACGATGACAG-
ACACTTTCC-3′), 0.75 mL of 20 mmol/L primer 6200R (5′-
CCCATGATGATGATGGCTTCCAGTATGC-3′), 0.2 mL Plat-
inum Taq (Invitrogen), and water to make up a 50-mL reaction
volume. Conditions for the second round were an initial in-
cubation at 95C for 4 min, followed by 35 cycles of 94C for
30 s, 57C for 30 s, and 72C for 45 s, and a final incubation
of 72C for 7 min. The resulting fragment was 259 bp in size.
Reactions were performed under strict conditions to avoid
contamination. Master mix reagents were prepared in DNA-
free areas in hoods subject to UV decontamination. DNA tem-
plates were prepared and added to the reaction in separate
hoods. PCR products were run on 1% agarose gels stained with
ethidium bromide in a third area, away from PCR machines
and hoods.
For ex vivo T cell ELISPOT assays, 96-well plates were coated
with anti-interferon-g immunoglobulin G, to which peptide
pools and between 100,000 and 200,000 PBMCs were added,
in duplicate. After incubation, biotinylated interferon-g anti-
body was added. Following addition of a streptavidin-labelled
chromogen, the number of reactive cells was counted. Sixty-
six overlapping peptides covering the XMRV Gag protein were
synthesized as 18-mer peptides, overlapping by 10 amino acids
and tested in pools containing 11 peptides (final concentration,
2 mg/mL of each peptide). Assay results were considered to be
positive if the mean number of spot-forming units in the test
wells was greater then the mean plus 3 times the standard
deviation of the negative control well spot-forming units. As-
says with high background (110 spots/well) in the negative
control wells were excluded.
Results and discussion. We tested DNA extracted from
PBMCs from 84 patients who were chronically infected with
HIV-1. For all patients, the PCR for hGAPDH was positive,
confirming the presence of amplifiable DNA. We detected no
XMRV DNA by either the env or gag PCR reactions from
patient samples (Table 2), whereas in all reactions, 2 positive
controls containing ∼5 and ∼50 copies of XMRV, respectively,
amplified successfully. We tested plasma from 79 drug-naive
individuals recently infected with HIV-1 by reverse transcrip-
tion PCR. No patient samples were positive for XMRV gag or
env RNA (Table 2). Genomic DNA extracted from the blood
of 67 patients with hepatitis C virus (HCV) infection was tested
for the presence of XMRV gag and env viral DNA. Positive
XMRV controls and the hGAPDH house-keeping gene ampli-
fied successfully, but no samples were positive for XMRV (Table
2). In summary, of 230 patients tested, 0 (95% confidence in-
terval, 0%–1.3%) had positive results by PCR for either XMRV
env or gag.
Following the absence of positive results with PCR, we de-
veloped a novel ex vivo ELISPOT assay to identify T cell re-
sponses in PBMCs to the XMRV Gag protein. T cell ELISPOT
assays are a sensitive tool for detecting immune responses to
infecting pathogens and have become a routine component of
clinical diagnostics, for example, to screen for latent Mycobac-
terium tuberculosis infection. The PBMCs tested in an ELISPOT
assay can either be ex vivo or “cultured.” We chose the ex vivo
approach because it is both sensitive and specific for the de-
tection of effector T cell responses to active infections with
retroviruses and other pathogens, whereas cultured ELISPOT
assays are more appropriate for detecting rare or weak non-
infective memory responses, for example, those induced by
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vaccines. Here, we used T cell ELISPOT assays with use of 18
amino acid overlapping peptides from XMRV Gag to look for
evidence of XMRV infection in PBMCs from 49 patients with
acute HIV-1 infection and 14 patients with HCV infection. We
targeted the XMRV Gag gene, as in other retroviral infections,
the Gag protein is highly expressed and is recognized by T cells
[13]. In the original report of XMRV in patients with chronic
fatigue syndrome, XMRV Gag was detectable by Western blot
in lysates of patient PBMCs [3]. We found no positive responses
in the 63 patients studied, giving an estimated prevalence of
0% (1-sided 95% confidence interval, 0%–4.7%), providing no
evidence of enrichment for XMRV infection in this cohort. As
controls, PBMCs were tested with phytohemaglutinin and FEC
(influenza, Epstein-Barr virus, and human cytomegalovirus)
antigens. Peptides that are 18 amino acids long will bind to
both human leukocyte antigen class I and class II, and the assay
is designed to detect both cytotoxic T cell (CD8) and T helper
cell responses (CD4). Although widely used to detect T cells
targeting retroviral peptides, this is the first time ELISPOT
assays have been applied for the detection of responses to
XMRV, and the result must be interpreted in the context of
the lack of PCR-positive samples to act as positive controls.
However, patient cells were responsive to other antigens, such
as phytohemaglutinin or FEC, suggesting that the lack of re-
sponses simply reflects an absence of XMRV Gag-specific T
cells in our cohort.
The identification of a previously unreported retrovirus in
the human population may have profound implications. The
2 classes of known human retroviruses (HIV-1 and human T-
lymphotropic virus) are pathogenic, and murine leukemia virus
gene therapy vectors have caused insertional mutagenesis in
children treated for X-linked immunodeficiency [14]. In our
cohorts of patients with HIV-1 or HCV infection, we found
no evidence of XMRV infection in blood, consistent with some
of the studies on chronic fatigue syndrome [7–9]. XMRV DNA
has been found within malignant prostate tissue, and XMRV
can be cultured in a prostate cancer cell line, LNCaP. In vitro
studies show that XMRV has an affinity for prostate cancer
cells but is much less infectious for other cell types [15]. We
are not aware of any studies in which the PBMCs of patients
with XMRV-positive prostate cells have also been tested. It is
therefore possible that in a compartmentalized infection,
XMRV may not be represented in blood, and our data must
be interpreted in this light. However, because all the studies of
patients with chronic fatigue syndrome have used PBMCs, this
is the context in which our study was set.
We hypothesized that if XMRV is present in the United
Kingdom or Switzerland and is spread by either sexual or
blood-borne routes, we might expect to see it enriched in the
blood of patients with HIV-1 or HCV infection. We did not
detect XMRV in any patients. Together, the results of PCR
reactions for 230 patients and the paired ELISPOT assays are
evidence that XMRV is not enriched in patients who are at risk
of blood-borne and sexually transmitted infections in the
United Kingdom and Western Europe.
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